UK markets open in 6 hours 46 minutes

Arch Biopartners Inc. (ARCH.V)

TSXV - TSXV Real-time price. Currency in CAD
Add to watchlist
1.7500-0.0400 (-2.23%)
At close: 03:59PM EDT
Full screen
Previous close1.7900
Open1.8300
Bid1.7400 x 0
Ask1.7700 x 0
Day's range1.7300 - 1.8300
52-week range0.9700 - 2.5600
Volume23,730
Avg. volume29,503
Market cap109.997M
Beta (5Y monthly)1.34
PE ratio (TTM)N/A
EPS (TTM)-0.0300
Earnings date28 May 2024 - 03 Jun 2024
Forward dividend & yieldN/A (N/A)
Ex-dividend date13 Sept 2000
1y target estN/A
  • GlobeNewswire

    St. Michael’s Hospital Joins the Phase II Trial of LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury

    TORONTO, April 16, 2024 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced today that a research team from St. Michael’s Hospital, a site of Unity Health Toronto, has joined the Phase II trial for LSALT peptide targeting the prevention and treatment of cardiac surgery-associated acute kidney injury (CS-AKI). LSALT peptide is the Company’s lead drug candidate for preventing and treating inflammation injury in the kidneys, lungs and

  • GlobeNewswire

    UHN Joins the Phase II Trial of LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury

    TORONTO, April 03, 2024 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced today that Anesthesia Clinical Trials Unit (ACTU), an academic research organization in the Department of Anesthesia and Pain Management at the University Health Network (UHN), has joined the Phase II trial for LSALT peptide targeting the prevention and treatment of cardiac surgery-associated acute kidney injury (CS-AKI). LSALT peptide is the Company’s lead

  • GlobeNewswire

    Arch Biopartners Adds Three New Clinical Sites into the Phase II Trial for LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury

    TORONTO, April 02, 2024 (GLOBE NEWSWIRE) -- Arch Biopartners Inc., (“Arch” or the “Company”) (TSX Venture: ARCH and OTCQB: ACHFF), announced today that three additional clinical sites in Turkey have joined the Phase II trial for LSALT peptide targeting the prevention and treatment of cardiac surgery-associated acute kidney injury (CS-AKI). LSALT peptide is the Company’s lead drug candidate for preventing and treating inflammation injury in the kidneys, lungs and liver. The three new hospitals jo